In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
Judy Garber, MD, MPH
Advertisement
Articles by Judy Garber, MD, MPH
Advertisement
Latest Updated Articles
Judy Garber on PARP Inhibitors for Triple-Negative Breast CancerPublished: November 15th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
